Prise en charge néonatale des formes sévères d’incompatibilités fœtomaternelles érythrocytaires

摘要

Diagnosis and management of feto-maternal red blood cell incompatibilities are a regular concern for neonatologists on maternity wards. Despite of the tremendous development of antenatal and post-natal therapies and prevention, haemolytic disease of the newborn has not disappeared. ABO incompatibility is the most frequent cause of neonatal haemolytic disease (HDN), and RH4, RH3, and KEL1 are today increasing compared to RH1 disease. The management of HDN begins in the perinatal period and will end after 2–3 months post-natal age. Its success relies on anticipation and close interactions in between obstetricians, neonatologists, biologists, and transfusion team.